⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LYEL News
Lyell Immunopharma, Inc. Common Stock
Form 8-K
sec.gov
LYEL
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
globenewswire.com
LYEL
Form 8-K
sec.gov
LYEL
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
globenewswire.com
PRQR
LYEL
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
globenewswire.com
LYEL
PRQR
Keros Therapeutics Appoints Charles Newton to its Board of Directors
globenewswire.com
KROS
LYEL
CHRS
Lyell Immunopharma Announces Participation in March Investor Conferences
globenewswire.com
LYEL
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
globenewswire.com
GTBP
LYEL
CRBU
SLS
NRIX
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
prnewswire.com
GTBP
REGN
GMAB
AUTL
LYEL
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
globenewswire.com
LYEL